Proteomics of Mycobacterium tuberculosis Beijing genotype after acquisition of Isoniazid resistance

ABSTRACT: This project provides the first characterization of protein differences in clinical isolates of Mtb after acquisition of resistance to isoniazid (INH), one of the most important drug treatment options against TB. This study determines the global protein differences in a clinical isogenic pair of Mtb, comparing INH susceptibility versus INH resistance.

INSTRUMENT(S):

ORGANISM(S): Mycobacterium Tuberculosis H37rv

TISSUE(S): Prokaryotic Cell

DISEASE(S): Pulmonary Tuberculosis

SUBMITTER: Luisa Nieto  

LAB HEAD: Karen M. Dobos

PROVIDER: PXD002986 | Pride | 2016-03-14

REPOSITORIES: Pride